<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03435094</url>
  </required_header>
  <id_info>
    <org_study_id>LAB-BIN-001</org_study_id>
    <nct_id>NCT03435094</nct_id>
  </id_info>
  <brief_title>Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes</brief_title>
  <official_title>A Non-interventional Two-arm Two-centre, Retrospective/Prospective Study to Compare the Effect of Alendronate 70mg Formulation (Tablet vs Effervescent Tablet) on Bone Turnover Markers and Patient Reported Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Labatec Pharma SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Labatec Pharma SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the data obtained with two formulations of alendronate 70 mg (tablets vs effervescent
      tablet for buffered solution) on the change in bone turnover markers, on gastric tolerance
      and on treatment adherence (including compliance and persistence).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 25, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>s-CTX</measure>
    <time_frame>Change at 6 months, 12 months, 18 months after treatment start</time_frame>
    <description>Decrease in the rate of the bone resorption marker s-CTX</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Osteoporosis, Postmenopausal</condition>
  <arm_group>
    <arm_group_label>Fosamax®</arm_group_label>
    <description>1 group will be treated with alendronate 70 mg tablets (Fosamax®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Binosto®</arm_group_label>
    <description>1 group will be treated with alendronate 70 mg effervescent tablets for buffered solution (Binosto®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Binosto 70Mg Effervescent Tablet</intervention_name>
    <description>Assess the effect of alendronate 70mg effervescent tablet on bone turnover markers and patient reported outcomes.</description>
    <arm_group_label>Binosto®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosamax 70Mg Tablet</intervention_name>
    <description>Assess the effect of alendronate 70mg tablet on bone turnover markers and patient reported outcomes.</description>
    <arm_group_label>Fosamax®</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Post-menopausal women with osteoporosis, on treatment with Fosamax® or Binosto® for 6-8
        months and who will be continued to be treated for a minimum of 12 months, with available
        BTMs, biochemistry and DXA at the initiation are to be offered participation in the study
        at the discretion of the treating physician.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post-menopausal women (at least 5 years after natural / surgical menopause).

          -  Patients on treatment with alendronate 70mg tablets or alendronate 70mg effervescent
             tablets for 6-8 months and who will be continued to be treated for a minimum of 12
             months.

          -  Available BTMs (s-CTX), biochemistry (calcium, phosphate, 25-OH vit D, PTH,
             creatinine) and DXA (lumbar spine, total hip and femoral neck) at the initiation of
             the treatment.

          -  Ability to sign an informed patient consent

        Exclusion Criteria:

          -  Patients who had received a prior osteoporosis treatment with anti-resorptive drugs
             (bisphosphonate or denosumab) or teriparatide before starting alendronate 70 mg.

          -  Any secondary cause of osteoporosis including current treatment with glucocorticoids
             or aromatase inhibitors, inflammatory disorders, malabsorption

          -  Metabolic or cancer bone disease

          -  Contra-indications to bisphosphonates according to product labelling

          -  Known or suspected allergy to study product(s) or related products

          -  Inability to sign an informed consent

          -  Previous participation in this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aurélie TIREFORD, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Labatec Pharma SA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurélie TIREFORD, PharmD</last_name>
    <phone>+41 22 593 78 54</phone>
    <email>aurelie.tireford@labatec.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Endokrinologische Praxis &amp; Labor</name>
      <address>
        <city>Basel</city>
        <state>BS</state>
        <zip>4055</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Meier, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire de Genève, Service des maladies osseuses</name>
      <address>
        <city>Genève</city>
        <state>GE</state>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Serge Ferrari, Prof</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2018</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

